Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Same author

<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor Types.

JCO precision oncology·2026

Same author

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Precision Oncology: 2024 in Review.

Matteo Repetto¹, Nicole Fernandez², Alexander Drilon^1,3

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Discovery

|December 2, 2024

Summary

Precision oncology in 2024 is advancing rapidly. Key developments include better patient selection using predictive molecular markers and improved combination therapies through rational drug design and repurposing.

More Related Videos

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Experiment Videos

Last Updated: Jun 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Area of Science:

Oncology
Genomics
Pharmacology

Background:

Precision oncology aims to tailor cancer treatment to individual patients.
Identifying predictive molecular events is crucial for effective patient selection.
Advances in drug development are essential for improving therapeutic outcomes.

Purpose of the Study:

To summarize key advances in precision oncology during 2024.
To highlight evolving strategies in patient selection based on molecular markers.
To discuss progress in combination therapies, small-molecule inhibitor design, and drug repurposing.

Main Methods:

Review of recent literature and clinical trial data in precision oncology.
Analysis of emerging predictive molecular biomarkers.
Evaluation of novel therapeutic strategies including combination regimens and drug design.

Main Results:

Significant progress in identifying and utilizing predictive molecular events for patient stratification.
Advancements in developing strategic combination therapies.
Innovations in rational drug design for small-molecule inhibitors and structure-informed drug repurposing.

Conclusions:

Precision oncology continues to evolve with significant 2024 advancements.
Improved molecular profiling enhances patient selection for targeted therapies.
Novel drug development and repurposing strategies promise more effective cancer treatments.